Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction

Blood

Volumn 100, Issue 8, 2002, Pages 2874-2881

  Guerra, Nadia ^a,b   Michel, Frédérique ^a,b   Gati, Asma ^a,b   Gaudin, Catherine ^a,b   Mishal, Zohar ^a,b   Escudier, Bernard ^a,b   Acuto, Oreste ^a,b   Chouaib, Salem ^a,b   Caignard, Anne ^a,b,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSTITUT PASTEUR   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD158 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN RECEPTOR; LAT PROTEIN; PROTEIN; PROTEIN KINASE ZAP 70; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VAV PROTEIN;

ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOSKELETON; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY CARCINOMA; KILLER CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR CELL CULTURE;

EID: 0037108305     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0643     Document Type: Article

References (50)

1. Lanier L. NK cell receptors. Ann Rev Immunol. 1998;16:359-393.
2. Braud VM, Allan DS, Callaghan AO, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795-795.
3. Colonna M, Navarro F, E, Bellon T, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 1997;186: 1809-1818.
4. Cosman DN, Franger L, Borges M, et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 1997; 7:273-282.
5. Binstadt BA, Brumbaugh KM, Dick CJ, et al. Sequential involvement of Lck and SHP-1 with MHC recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity. 1996;5:629-638.
6. Long EO. Regulation of immune responses by inhibitory receptors. Adv Exp Med Biol. 1998;452: 19-28.
7. Vitale M, Sivori S, Pende D, et al. Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class I: their role in the definition of different groups of alloreactive NK cell clones. Proc Natl Acad Sci U S A. 1996; 93:1453-1457.
8. Ferrini S, Cambiaggi A, Meazza R, et al. T cell clones expressing the natural killer cell related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function. Eur J Immunol. 1994;24:2294-2298.
9. Mingari MC, Schiavetti F, Ponte M, et al. Human CD8+ T lymphocyte subsets that express HLA class I specific inhibitory receptors represent oligoclonally or monoclonally expanded populations. Proc Natl Acad Sci U S A. 1996;93:12433-12438.
10. Young NT, Uhrberg M, Phillips JH, Lanier LL, Parham P. Differential expression of leukocyte receptor complex Ig like receptors correlates with the transition from effector to memory. J Immunol. 2001;166:3933-3941.
11. Ugolini S, Arpin C, Anfossi N, et al. Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells. Nat Immunol. 2001;2:430-435.
12. Phillips JH, Gumperz JE, Parham P, Lanier LL. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science. 1995;268:403-405.
13. Mingari MC, Ponte M, Vitale C, Bellomo R, Moretta L, Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum Immunol. 2000;61:44-50.
14. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6:199-208.
15. Bakker AB, Phillips JH, Figdor CG, Lanier LL. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells and antigen-specific CTL. J Immunol. 1998;160:5239-5245.
16. Mingari MC, Moretta A, Moretta L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T cell responses. Immunol Today. 1998;19:153-157.
17. Guerra N, Guillard M, Angevin E, et al. Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor specific T lymphocytes infiltrating renal cell carcinoma. Blood. 2000;95:2883-2889.
18. Qian D, Weiss A. T cell antigen receptor signal transduction. Curr Opin Cell Biol. 1997;9:205-212.
19. Finco TS, Kadlecek T, Zhang W, Samelson LE, Weiss A. LAT is required for TCR-mediated activation of PLCgamma1 and the Ras pathway. Immunity. 1998;9:617-626.
20. Bunnell SC, Kapoor V, Trible RP, Zhang W, Samelson LE. Dynamic actin polymerization drives T cell receptor-induced spreading: a role for the signal transduction adaptor LAT. Immunity. 2001;14:315-329.
21. Fisher KD, Kong YY, Nishina H, et al. Vav is a regulator of cytoskeletal reorganization mediated by the T cell receptor. Curr Biol. 1998;8:554-558.
22. Holsinger LJ, Graef IA, Swat W, et al. Defects in actin-cap formation in vav-deficient mice implicate an actin requirement for lymphocyte signal transduction. Curr Biol. 1998;8:563-572.
23. Krause M, Sechi AS, Konradt M, Monner D, Gertler FB, Wehland J. Fyn binding protein (Fyb)/SLP-76-assocaited protein (SLAP), Ena/vasodilatator-stimulted phosphoprotein(VASP) proteins and the Arp2/3 complex link T cell receptor (TCR) to the actin cytoskeleton. J Cell Biol. 2000; 149: 181-194.
24. Xavier R, Bennan T, Li Q, McCormack C, Seed B. Membrane compartmentation is required for efficient T cell activation. Immunity. 1996;8:723-733.
25. Janes P, Ley S, Magee A. Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. J Cell Biol. 1999;147:447-461.
26. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science. 1999;283:680-682
27. Speiser DE, Pittet MJ, Valmori D, et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma specific cytolytic T lymphocytes. J Exp Med. 1999;190:775-782.
28. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260: 3440-3450.
29. Leupin O, Zaru R, Laroche T, Muller S, Valitutti S. Exclusion of CD45 from the T cell receptor signaling area in antigen stimulated T lymphocytes. Curr Biol. 2000;10:277-280,
30. Bléry M, Olcese L, Vivier E. Early signaling via inhibitory and activating NK receptors. Hum Immunol. 2000;61:51-64.
31. Su MW, Yu CL, Burakoff SJ, Jin YJ. Targeting Src homology 2 domain-containing tyrosine phosphatase (SHP-1) into lipid rafts inhibits CD3 induced T cell activation. J Immunol. 2001;166:3975-3982.
32. Bichler KH, Kleinknecht S, Strohmaier WL. Immune status and immune therapy of renal cell carcinoma. Urol Int. 1990;45:269-283.
33. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993;53:5613-5616.
34. Kolenko V, Wang Q, Riedy MC, et al. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 and IL-2 receptor signaling: role of soluble products from renal cell carcinomas. J Immunol. 1997;159:3057-3067.
35. Gati A, Guerra N, Giron-Michel J, et al. Tumor cells regulate the lytic activity of tumor-specific cytotoxic T lymphocytes by modulating the inhibitory natural killer receptor function. Cancer Res. 2001;61:3240-3244.
36. Fahmy T, Bieler J, Edidin M, Schneck J. Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity. 2001;14:135-143.
37. Vales-Gomez M, Reyburn H, Mandelboim M, Strominger J. Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity. 1998;9:337-344.
38. Zhang W, Sloan-Lancaster J, Kitchen J, Trible R, Samelson L. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell. 1998;92:83-92.
39. Harder T, Kuhn M. Selective accumulation of raft-associated membrane protein LAT in T cell receptor signaling assemblies. J Cell Biol. 2000;151: 199-207.
40. Wulfing C, Davis MM. A receptor/cytoskeletal movement triggered by costimulation during T cell activation. Science. 1998;282:2266-2269.
41. Crespo P, Schuebel K, Ostrom A, Gutkind J, Bustelo X. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature. 1997;385:169-172.
42. Villalba M, Bi K, Rodriguez F, Tanaka Y, Schoenberger S, Altman A. Vavl/Rac-dependent actin cytoskeleton reorganization is required for lipid rafts clustering in T cells. J Cell Biol. 2001;155: 331-338.
43. Lanzavecchia A, Sallusto F. From synapses to immunological memory: the role of sustained T cell stimulation. Curr Opin Immunol. 2000;12:92-98.
44. Bromley SK, Burack WR, Johnson KG, et al. The immunological synapse. Annu Rev Immunol. 2001;19:375-396.
45. KupferA, Singer SL, Dennert G. On the mechanism of unidirectional killing in mixtures of two cytotoxic T lymphocytes. Unidirectional polarization of cytoplasmic organelles and the membrane-associated cytoskeleton in the effector cell. J Exp Med. 1986;163:489-498.
46. Stinchcombe J, Bossi G, Booth S, Griffiths G. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity. 2001;15:751-761.
47. Dietrich J, Cella L, Colonna M. Ig-like transcript 2 (ILT-2)/leukocyte ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol. 2001;166:2514-2521.
48. Moser J, Gibbs J, Jensen P, Lukacher A. CD94-NKG2A receptors regulate antiviral CD6+ T cell responses. Nat Immunol. 2002;3:189-195.
49. Childs R, Chernoff A, Cententin N, et al. Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cells transplantation. N Engl J Med. 2000;343: 750-758.
50. Childs R, Drachenberg D. Allogeneic stem cell transplantation for renal cell carcinoma. Curr Opin Urol. 2001;11:495-502.